An international phase-2 trial of a CAR-T cell therapy—to be published on-line Dec. 1 in the New England Journal of Medicine (and presented at the ASH annual meeting in San Diego)—found that 52 percent of patients responded ...
Dec 2, 2018
In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients ...
Dec 2, 2018
New drugs that harness the body's immune system to destroy cancer cells appear to increase the effectiveness of later drug therapies for non-Hodgkin and Hodgkin lymphoma patients, new research suggests. This happens, scientists ...
Dec 2, 2018
